1. Top
  2. IR Information
  3. News Releases

News Releases

Oct.6,2017 A paragraph on AI-guided INTENDD® has been added.
Oct.5,2017 We will be attending BioJapan 2017 from October 11-13 (Wed-Fri).
Oct.4,2017 Dr. Takeshi Tanaka, the general manager of Drug Design lab gave a presentation titled "The Contribution of Entropy in Drug-Protein Binding" at the CBI annual meeting 2017 on 3rd October.
Oct.3,2017 On October 10th, we'll be attending the "European Biotech and Pharma Partnering Conference, Osaka 2017".
Sep.21,2017 We are now connected with Biocomo(add a banner)!
Aug.21,2017 Dr. Takeshi Tanaka, the general manager of Drug Design lab, published an article in the journal of Medical Science Digest.
Jul.18,2017 We have renewed our web site! and also started Twitter, please follow us!
Jul.18,2017 Dr. Matsuzaki, the head of Drug Design lab, contributed a section to the Encyclopedia of Artificial Intelligence (The Japanese Society for Artificial Intelligence Edition), which was published on July 10, 2017.
Jul.11,2017 On July 25th, Masato Hosoda, CEO, will give a presentation at the KANSAI seminar titled “Kansai in the new era opened by AI” hosted by BBTower, Inc.
Jul.6,2017 On July 24th, Masato Hosoda, CEO, will give a presentation at a symposium titled “Realization of a society of health and longevity via application of AI and Big-data” hosted by Institution for Biomedical Research and Innovation (IBRI)
Jul.5,2017 On July 7th, Masato Hosoda, CEO, will give a presentation at “Mie university - jurisprudence and medical science joint symposium” hosted by Graduate School of Medicine, Mie University
May.30,2017 Dr. Matsuzaki, the head of Drug Design Lab, gave a poster presentation titled “True Landscape of Drug-Protein Binding” at JCUP VIII, an annual science meeting held by OpenEye Scientific Software Inc.
Sept.20,2016 New York Medical College and Interprotein Announce Research Partnership Agreement on Drug Discovery Research for small molecule PPI Inhibitors
Apr.25,2016 Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement
Nov.19,2015 Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
Dec.15,2014 Adoption of the subject that Interprotein has applied as a subject for A-STEP
Mar.20,2014 Participation of Interprotein in the space experiment for generation of high-quality protein crystals in "Kibo"
Nov.25,2013 Adoption of conformationally-constrained peptide (MicroAntibody) binding to vascular endothelial growth factor (VEGF) as a subject for A-STEP
Nov.16,2013 Dr.Takao Matsuzaki,Head of Drug Design Lab gave a lecture on ASDD 2013-BIT?fs 1st Annual Symposium of Drug Designology 2013.
Sep.2,2013 The first result of assessment of small molecule protein-protein interaction (PPI) inhibitors identified by the collaborative research between RaQualia and Interprotein
Apr.19,2013 Agreement on molecular design of small molecule protein-protein interaction (PPI) inhibitor between Interprotein Corporation and Takeda Pharmaceutical Company Limited
Feb.1,2013 RaQualia and Interprotein Announce Collaborative Research Agreement on Drug Discovery Research for PPI Inhibitors
Jan.30,2013 Interprotein made a presentation at the BIO Asia 2013.
Dec.4,2012 Adoption of peptide VEGF inhibitor (micro antibody) program as a subject for A-STEP
Nov.22,2012 Result of Assessment of Small molecule Protein-Protein Interaction (PPI) inhibitors Designed by Interprotein Corporation
Nov.15,2012 Adoption of small molecule IL-6 inhibitor program of Interprotein as a subject for A-STEP
Mar.19,2012 Interviews with leading Life Sciences companies: Interprotein, By Venture Valuation
Nov.21,2011 Ajinomoto Pharmaceuticals Co., Ltd. and Interprotein Corporation Sign a Joint R&D and Commercialization Agreement
Sep.30,2010 Interprotein and LegoChem Biosciences Sign Collaboration Agreement to Develop VEGF Inhibitor to Treat Solid Tumors
Sep.27,2010 Collaboration Agreement on Drug Discovery Research between Interprotein Corporation and Ajinomoto Pharmaceuticals Co., Ltd.
Nov.25,2009 Interviews with leading Life Sciences companies: Interprotein, By Venture Valuation
Nov.21,2008 Adoption of Interprotein?fs VEGF project in Super Special Consortia for supporting the development of cutting-edge medical care
Feb.27,2007 Evotec and Interprotein Sign Collaboration Agreement to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases
Jan.27,2006 Exclusive Patent Licensing of Degranulation Inhibiting Mechanism on Allergy-related Cells
Aug.9,2005 The announcement of Inter Cyto Nano Science and Dr. Jun Fujita, professor of the Kyoto University?Cagreed on a patent licensing of production yield improvement of recombinant protein